What if? <br>You could eliminate pre procedural steps for large bore vascular closure?, <br> You could heal and seal the arteriotomy from the inside?, <br> You could improve vascular complications? What if <br>You could manage Large-Bore vascular closure without any Pre-procedurall steps?, <br> You could heal and seal the arteriotomy from the inside?, <br> You … Home Read More »
Location: Ireland
Employees: 11-50
Total raised: $73.84M
Founded date: 2009
Investors 3
| Date | Name | Website |
| - | Panakes Pa... | panakes.it |
| - | Fountain H... | fh-partner... |
| - | Life Scien... | lspvc.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 13.03.2023 | - | $32.02M | - |
| 17.05.2022 | Series D | $23.13M | - |
| 07.10.2016 | - | $380.89K | - |
| 12.09.2016 | Series C | $18.3M | Fountain H... |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | David | Hochman | Board Obse... | linkedin.c... | - | - |
Mentions in press and media 20
| Date | Title | Description |
| 12.01.2026 | Nodu Raises $1.45M in Pre-Seed Funding | Nodu, a London, UK-based stablecoin infrastructure startup, raised $1.45M in pre-seed funding. The round was led by Digital Space Ventures (an early investor in Revolut and Paysend). The company intends to use the funds to expand operations... |
| 12.01.2026 | EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics | EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics Mon, Jan 12, 2026 07:30 CET Report this content EQT Life Sciences to exit portfolio company Vivasure Medical in sale to Haemonetics Vivasure’s PerQseal® Elite system uses a ... |
| 12.01.2026 | SYS Financial to acquire Portlaoise financial planner GTL Life and Pensions | SYS Financial has announced the acquisition of financial planning practice GTL Life and Pensions. The deal forms part of SYS Financial's expansion strategy and will bring its assets under management to €680m overall. The firm has further ac... |
| 09.01.2026 | Galways's Vivasure Medical acquired for up to €185m | Vivasure Medical, the Galway-based medical device company, has been acquired by the NYSE-listed Haemonetics Corporation in a deal worth up to €185m if certain conditions are met. Vivasure develops advanced polymer implants and delivery syst... |
| 14.11.2023 | Vivasure Medical Announces 100th Patient Enrolled in U.S. Pivotal Study | PATCH Clinical Study will evaluate the safety and efficacy of Vivasure’s PerQseal Closure Device System for large-bore vessel punctures Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel clo... |
| 13.03.2023 | Vivasure Medical Announces FDA IDE Approval to Initiate U.S. Pivotal Study | Pivotal study expected to be completed by year-end 2023 and set the stage for commercialization of PerQseal® system for large hole vessel closure Company announces €30 million strategic investment from Haemonetics as part of its previously... |
| 13.03.2023 | Vivasure Medical Receives €30M Investment from Haemonetics | Vivasure Medical, a Galway, Ireland-based company focused on absorbable technology for percutaneous vessel closure, received a €30m strategic investment from Haemonetics Corporation (NYSE: HAE) as part of its previously disclosed Series D f... |
| 17.05.2022 | Vivasure Medical Raises €22M in Series D Financing | Vivasure Medical, a Galway, Ireland-based company pioneering novel fully absorbable technology for percutaneous vessel closure, closed the first tranche of €22m as part of its Series D financing round that could reach up to €52m in total. L... |
| 17.05.2022 | Vivasure raises $23M initial Series D tranche; could reach up to $54M | Vivasure Medical announced today that it closed the first tranche — worth $23 million — of its Series D financing round. Galway, Ireland-based Vivasure’s $23 million (€22 million) fundraising tranche could make up a chunk of the Series D th... |
| 17.05.2022 | Vivasure Medical Announces Series D Financing to Advance Portfolio of PerQseal Vessel Closure Devices | Vivasure Medical® (“Vivasure” or the “Company”), a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the closing of the first tranche of €22 million ($23M) as part of its Series D financ... |
Show more